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ABSTRACT
Objective: This review article explores solid dispersions (SDs) as one of the suitable approaches to formulate poorly water-soluble drugs. The objective 
of this review on SD techniques is to explore their utility as a feasible, simple, and economically viable method for augmentation of dissolution of 
hydrophobic drugs.
Methods: Various types of SDs are classified and compared. Use of surfactants to stabilize the SDs and their potential advantages and disadvantages has 
been discussed. Different techniques for preparing and evaluating SDs are appraised along with discussions on scalability and industrial production. 
Review of the current research on SD along with future trends is also offered.
Results: Based on the various researches, SDs offer an efficient means of improving bioavailability while concurrently contributing to lower toxicity 
and dose-reduction.
Conclusion: Solid-dispersions have been and continue to be one of the key technologies for solving the issue of poor solubility for newer hydrophobic 
molecules which are being discovered. This would give a new lease of life for such drugs enabling them to be delivered in an effective way.
Keywords: Amorphous, Dissolution rate, Hydrophobic drugs, Solid dispersions, Solubility enhancement.
INTRODUCTION
Active pharmaceutical ingredients (APIs) have been classified on the 
basis of their water solubility and permeability through the intestinal 
mucosa as per the biopharmaceutical classification system (BCS) [1]. 
The chief factors which affect absorption of APIs through intestinal 
mucosa after oral administration are their rate of dissolution, solubility, 
and permeability. The challenge lies with APIs belonging to BCS Class II 
or Class IV. In general, the rate limiting step for absorption of the drugs 
in these classes is the low dissolution velocity emerging from low 
solubility.
Nearly, more than 90% of drugs are orally administered. The 
bioavailability of APIs is directly related to their solubility or rate 
of dissolution in water and/or biological fluids which are primarily 
aqueous in nature. Nearly, one-third of all under development new 
drugs/chemical entities are poorly water-soluble and are, therefore, 
difficult to formulate. Hydrophobic drugs often encounter problems 
such as poor absorption which may lead to inadequate and mutable 
bioavailability. Hydrophobic APIs will display absorption kinetics based 
on the rate-limiting step of dissolution, and those APIs with insufficient 
permeability will demonstrate permeation - rate limited absorption 
kinetics [1]. Noyes–Whitney equation suggests that the aqueous 
solubility of an API is directly related to the its rate of dissolution 
and consequently it is a significant variable that regulates the rate of 
dissolution and thereby the absorption [2].
To increase their solubility, numerous methodologies have been 
suggested such as alterations in physical form. These include a decrease 
in particle size to micrometers/nanometers and use of complexing 
agents, cosolvents, solubilizers, and surfactants. In addition, modification 
of crystal habit has been suggested which includes changing it to a 
more soluble polymorphic form or changing the crystalline form to 
an amorphous form solid dispersion (SD). Further, drug dispersion 
in hydrophilic carriers, formulation of lipid-based dosage forms and 
chemical modifications such as changes in pH and alteration in the salt 
form have also been suggested.
In this review, the description of SDs as a simple and cost-effective tool 
for dissolution enhancement has been discussed.
SDS
SDs are solid state systems where one or more APIs are mixed intimately 
with an inert substance which can be a hydrophilic polymer(s) or 
matrix forming agents [3]. The nature of the carrier can be crystalline 
or amorphous. The augmentation in the rate of dissolution of APIs 
made into SDs is credited to following reasons [4]:
•	 Molecular	dispersions	result	 in	 the	reduction	of	particle	size	and	
increase in surface area.
•	 Conversion	of	crystalline	APIs	into	amorphous	systems	results	in	the	
enhancement of the rate of dissolution. This is attributed to the lack 
of energy requirements during the dissolution process to break up 
the amorphous structure, unlike the organized crystalline state.
•	 Increase	in	wetting	properties	due	to	a	decrease	in	interfacial	tension,	





Based on the carriers used
This is depicted in Fig. 1.
First generation SDs
Carriers which are crystalline in nature are mixed with APIs to make 
SDs. Urea and sugar were amongst the first carriers used for the 
formulation of SDs [5]. However, such SDs have the serious drawback of 
having crystalline structures which are thermodynamically stable and, 
therefore, have greater energy needs for the disruption of the system 
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into solution. This adversely affects the release of a drug at a faster rate. 
Kalaiselvan et al. formulated SDs of albendazole to using crystalline 
carriers such as urea, polyethylene glycol (PEG) 6000, and poloxamer 
407 and achieved significant improvement in the dissolution profile of 
albendazole [6].
Second generation SDs
Amorphous carriers are the excipients of choice to formulate these SDs. 
Some of them include synthetic polymers such as hydroxypropyl methyl 
cellulose, ethyl cellulose, polymethacrylates, polyethylene oxides, 
polyvinylpyrrolidone (PVP), and naturally derived polymers such as 
starch derivatives like cyclodextrins. These result in an amorphous 
product which is thermodynamically less stable and releases drugs at a 
faster rate compared to their crystalline counterparts. Sharma and Jain 
have prepared SDs of carvedilol with amorphous carrier PVP K 30 using 
the solvent evaporation method [7].
Third generation SDs
To prepare these SDs, usually, a surfactant or a blend of polymers or 
a blend of surfactants and polymers are employed as carriers which 
exhibit self-emulsifying properties. Surfactants such as inulin, glyceryl 
behenate, and poloxamer 407 have been used as carriers in many 
preparations to enhance the dissolution profile of a drug. They are 
advantageous as the presence of surfactants prevents recrystallization 
and additionally enhances wettability and hence the dissolution 
rate. Patel and Joshi evaluated surfactants and their combinations as 
effective carriers in preparation of SDs [8].
Based on solid-state structure
Eutectic mixtures
A physical blend of two or more components that tends to reduce 
melting points when mixed in certain proportions leading to the 
formation of a mix that has melting point lower than the individual 
components is called a eutectic mixture. This was first used in context 
with SDs by Sekiguchi and Obi in 1961 [5]. In SDs composed of a eutectic 
blend, the API and the carrier are present as fine particles. This leads 
to an enormous increase in surface area and the enhancement rate of 
dissolution of the API. Sulfathiazole is known to be first formulated by 
this technique with urea as a carrier [3].
Solid solution
The SDs which are miscible in liquid, as well as the solid state, are 
termed as solid solutions. Based on the degree of miscibility of the 
API and the carrier, solid solutions are of two types; continuous and 
discontinuous solid solutions. In continuous solid solutions, the two 
components are miscible in the solid state in all proportions, whereas, 
in discontinuous solid solutions, the components are immiscible at 
intermediate composition, but miscible at the extreme of composition.
On the basis of the molecular size of the two components, the 
solid solutions are classified as substitutional and interstitial. In 
substitutional solid solutions, the solute molecules substitute the 
solvent molecules in the crystal lattice. While in the interstitial solid 
solutions, the dissolved molecules occupy the interstitial spaces 
between the solvent molecules in the crystal lattice. Examples include 
solid solutions of methyltestosterone, hydrocortisone acetate in the 
matrix of PEG 6000 [9].
In 1965, Goldberg et al. elucidated the advantages of solid solutions as 
compared to eutectic mixtures [10]. He mentioned that release of the 
drug is faster from solid solutions as the dissolution process does not 
consume the energy needed to disrupt the crystalline forms.
Based on the miscibility of drug and carrier
Immiscibility in fluid phase
In certain cases, where API and carriers are immiscible in their fluid 
phase, they may not demonstrate the desired miscibility even on 
solidification. Enhancement in dissolution rate of these type of drugs 
can be done through alteration in the morphology of the APIs and/or 
carriers due to changes in physical structure. The rate of solidification 
and the rate of crystal formation are the critical parameters that govern 
whether crystalline or amorphous SDs are formed.
Miscibility in the fluid phase
As both drugs and polymers are miscible in a fluid state, phase 
separation is expected (i.e., may or may not) during solidification, 
thereby influencing the structure of SD.
Methods for preparation of SD
The various methods are classified in Fig. 2.
Kneading technique
This is a simple method where drug and the polymer (carrier) are 
mixed in a predetermined ratio and kneaded with the solvent resulting 
in the formation of a paste formed that is dried and sieved.
SDs of indomethacin with lactose monohydrate and different 
polymers -polyethylene oxide - 6000, hypromellose, PVP, and 
β	 cyclodextrins	 -	 were	 prepared	 through	 the	 kneading	 method.	
A significant improvement in the dissolution and flow properties over 
raw indomethacin was observed [11]. This technique was successfully 
employed to augment the rate of dissolution of the hydrophobic drug, 
meloxicam using poloxamer 188 [12].
Melting/fusion technique
This involves melting of the carrier and the addition of the drug into the 
melted carrier with continuous mixing. The drug melts inside the heated 
carrier, and a homogenous melt mass is obtained [13]. The fused mass is 
cooled rapidly and kept in desiccating chamber for the predetermined 
time. The solidified mass is grinded, milled, and sieved. Revaprazan-
loaded SDs were prepared using hydroxypropylmethylcellulose which 
resulted in a significant enhancement of its dissolution property [14]. 
The method shows the benefits of being simple and economical and does 
not require any sophisticated instrumentation. However, its application 
is restricted to the combination of drug and carrier where both have 
nearly the same melting point and are stable at temperatures near their 
melting points. The cooling speed and temperature of the drugs and 
carriers are critical factors in obtaining a homogenous product.
Solvent evaporation method
The method involves choosing a solvent that has the capacity to dissolve 
drugs as well as the carriers. The API and the carrier are dissolved in 
the least possible volume of solvent with continuous stirring in two 
different containers. The drug solution is added to the carrier solution 
with continuous stirring. The solution is then evaporated under reduced 
pressure to yield dry product [15]. The dried mass is crushed and sieved 
and stored in desiccators. This method has the advantage over the melting 
method that the drug is not exposed to higher temperature. This method 
was employed to prepare SD of carbamazepine using PVP combined 
Fig. 1: Categorization of solid dispersions based on carriers 
employed
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with either Gelucire 44/14 or Vitamin E TPGS. The SDs showed higher 
dissolution rate as compared to pure carbamazepine [16].
Sometimes, a combination of melting and solvent method can be 
employed
In this case, the API is dissolved in a solvent in which it is freely soluble, 
the carrier is melted, and the API solution is added into the melt of the 
solid carrier. This blend is finally evaporated to yield a clear solvent-
free film. The drying of the film is continued until it attains a constant 
weight. This technique has the benefits of melting technique as well 
as solvent evaporation methods. This method is particularly useful for 
drugs that are thermolabile or have high melting points, but it is not 
suitable for drugs with a low therapeutic dose (below 50 mg).
Lyophilization method
This method is generally used as an alternate to the solvent evaporation 
method. Similar to the solvent evaporation method, this method also 
involves the choice of a common solvent in which the drug and the 
carrier are dissolved in a predetermined ratio. The solution containing 
the drug and the carrier is frozen and subjected to lyophilization where 
the frozen mass directly sublimes, and a porous SD is obtained. This 
is advantageous over solvent evaporation as it offers minimal thermal 
stress and chances of phase separation while the solvent is being 
removed. Dissolution enhancement of glyburide was achieved using 
this technique using different grades of PEGs as polymers [17]. SD of 
efavirenz - PVP K-30 produced through the lyophilization technique 
resulted in significant solubility enhancement of efavirenz [18].
Melt extrusion method
This method employs a corotating twin screw extruder. Here, the drug 
and the carrier are mixed together at their melting temperatures and 
the mix is extruded at a high rotational speed. Three processes, namely 
melting, homogenizing and then extrusion takes place simultaneously, 
and the product is shaped as desirable solid dosage form.
This technique involves a very brief exposure of the drug-carrier mix 
to an elevated temperature for a period of about one min. This enables 
even thermolabile drugs to be processed without being degraded. SD 
formulation of antiulcer drug lafutidine was successfully formulated 
using	hot	melt	extrusion	(HME)	technique,	and	it	was	demonstrated	that	
the SD of lafutidine performed better with immediate drug release as 
compared with pure lafutidine [19]. Agrawal et al. developed SDs using 
HME	technology	with	a	scale	up	from	mini	scale	to	clinical	scale	[20].
Electrospinning method
This method involves preparation of solid fibers by passing drug carrier 
melt or drug carrier blend in a fluid state through nozzles of millimeter 
scale. A strong electrostatic field is applied over a capillary which is 
attached to vessel which contains the aforesaid drug-carrier fluid blend 
or melts. This method is advantageous as it is can yield fibres in nano 
range, and it is simple and economical to perform. Researchers have 
made successful attempts to produce SDs of ketoprofen as nanofibers 
using PVP as the carrier [21]. Similarly, SDs of hydrophobic API 
piroxicam were prepared using hypromellose and nanofibers were 
produced using the electrospinning method [22].
Supercritical fluid method
This method uses the principle of precipitating out drug-carrier blends 
to form a common solvent using carbon dioxide as an anti-solvent. This 
approach is beneficial as it gives products in the micron to submicron 
range. In addition, it offers multiple advantages including the fact that 
supercritical carbon dioxide can be removed and that carbon dioxide 
is non-toxic and safe for patients even if some traces are left behind. 
Itraconazole was formulated into SD using supercritical fluid technique 
using hypromellose, Pluronic F-127, and L-ascorbic acid [23]. Similar 
attempts were made by researchers for poorly soluble API cefuroxime 
axetil using hypromellose and polyvinyl pyrrolidone as carriers [24].
Evaluation of SD
The evaluation is carried out by studying the effect on the dissolution 
rate of drug after being formulated into SDs. In addition, solid-state 
characterization of the SDs must be done and compared with that of 
pure drug. The details of these evaluation tests are discussed below.
Comparative dissolution rate studies
This is done by comparing the in vitro dissolution release profiles of 
the marketed product or pure drug, the physical mixture of drug and 
polymer used in SD and the SD itself. For immediate release products, a 
model-independent approach can be followed which involves calculation 
of difference factor (f1) and similarity factor (f2) between two dissolution 
profiles following dissolution method [25]. Dissolution conditions can 
be chosen based on the specifications recommended in the United States 
Food and Drug Administration (US FDA) database or official books.
Solid state characterization
This is performed by employing the following techniques:
a. Differential scanning calorimetry (DSC)
b. X-ray diffraction study (XRD)
c.	 Scanning	electron	microscopy	(SEM).
d.	 Diffuse	reflectance	infrared	Fourier	transform	spectroscopy	(DRIFTS)
e. Residual solvent content determination
f. Effect of aging.
DSC
DSC is done to comprehend the thermal behavior of the product [26]. 
This includes heating of samples at a predetermined rate which is mostly 
10°C/min, till their melting point. The height of endothermic peak and 
heat of fusion is studied, and the physical mixture and the pure drug are 
compared. Any reduction in endothermic peak suggests partial conversion 
of the crystalline drug into amorphous and the complete disappearance of 
endothermic peak suggests total conversion of the drug from crystalline 
to amorphous form. This polymorphic transition is favorable as it leads to 
faster dissolution rate due to reduced energy requirement for breaking the 
disordered molecular structure in the amorphous product as compared to 
the highly ordered lattice in the crystalline product.
X-ray powder diffraction (XRPD)
XRD is a critical tool used for the study of crystal structures and atomic 
spacing [27]. The scattering of X-rays from atoms produces a diffraction 
pattern	 that	 is	 characteristic	 of	 their	 arrangement.	 Monochromatic	
X-rays are produced by the cathode ray tube is focused toward the 
powder sample. The rays are diffracted which are characteristic of the 
crystal structure of powder sample. These diffracted rays are sensed 
and counted. Physical characterization of SD is done by studying the 
absence of peak of crystallinity.
The detection is based on Bragg’s law which says that radiation of 
wavelength	λ	incident	on	a	series	of	planes	with	periodic	spacing	d	will	
be	diffracted	through	an	angle	θ	where,
Fig. 2: Various methods for preparing solid dispersions
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composition [28]. In this technique, the double-sided carbon tape is 
attached on aluminum stubs, and powder sample is sprinkled onto the 
tape. The aluminum stubs are positioned in the vacuum chamber, and 
the morphological portrayal and surface characteristic of the sample 
are studied using the electron beam.
DRIFTS
Drug carrier interaction studies can be performed through this 
technique. This is done using an FTIR spectrometer equipped with a 
diffuse reflectance attachment and a data station [29]. This involves 
preparation of KBr pellets after mixing it with the sample to be analyzed 
and scanning it at a wavelength range from 4000 to 400 cm-1. The spectra 
obtained are characteristic of the atomic arrangement in molecules. 
If the characteristic peaks of the drug and polymer are present in SD, 
it indicates that the drug and the polymer do not have any chemical 
interaction and will not alter each other’s stability.
Residual solvent content determination
This is required where organic solvents are being used for the 
preparation of SD to ensure that they are present in quantities lower 
than their toxicity levels [30]. This is achieved using Karl Fischer 
titration and thermal gravimetrical analysis.
Aging effect
The SD is stored at 30°C/65% RH for 3 months, and the dissolution rate 
profile is performed to see the effect of aging in drug release. DSC and 
XRPD studies are performed and compared with the freshly prepared 
product to observe any change in the crystal structure.
Scalability and industrial applications
SDs have been reported to have drawbacks with respect to their 
large-scale preparation due to the onerous processes of preparation 
involving careful and subtle adjustments during their developmental 
stages. Furthermore, concerns about the stability of the API within 
its vehicle are a major issue which impacts the shelf-life of the 
product. However, on the positive side, efforts to overcome these 
hurdles have yielded promising results. The techniques to improve 
industrial application, scalability along with stability are discussed 
below:
Capsugel® technology
It was innovated by bend research as a pioneering technology which 
employed a spray-dried dispersion (SDD) method [31]. It presented a 
single-phase, amorphous molecular dispersion of API in a polymeric 
matrix where the API is molecularly dissolved within a solid mass. 
SDDs were acquired by adding API and polymer to an organic solvent 
and then spray-dried. The process parameters were selected in such 
a way so as to ensure that the solvent evaporated rapidly from the 
globules, permitting inadequate time for phase separation or crystal 
formation. SDDs have revealed enduring stability supplementing 
their established results in solubility enhancement, simplistic 
scale-up, and admirable manufacturing capability. Expiration dates 
extending beyond 2 years have been reliably exhibited with SDDs. 
Manufacturability	 has	 been	 consistently	 exhibited	 at	 levels	 ranging	
from milligrams up to tons.
Free flowing sugar coated bead
It is a novel technique which yielded APIs dispersed within a polymeric 
solution which is dried, and then coated with sugar solution to form 
free-flowing particles [32]. Such an oral dosage form is largely 
devoid of any residue of methylene chloride. The method consists of 
making a working solution made up of an alcohol, a strong acid, API, 
a water-soluble polymer, and water. Itraconazole-coated particles have 
been successfully formulated using this technique.
HME
HME	 is	 enormously	 adaptable for making industrial-scale SD [33]. 
The chief benefit is that solvents are not needed. This circumvents the 
possibility of any residual solvent which may hamper stability and shelf 
life. For example, in research work, miconazole SDs were prepared by 
HME.	Miconazole	was	dissolved	with	the	PEG	portion	of	the	copolymer	
or was yielded as crystals in the identical or a dissimilar polymorph as 
the starting substance. The kinetic miscibility was found to be greater 
for	 the	 HME-SDs	 produced	 from	 solutions	 that	 were	 pre-heated	 in	
comparison with the spray-dried formulations. Furthermore, greater 
amount	 of	 drug	was	 incorporated	 into	HME-SD	 than	 the	 spray-dried	
product [34].
Filling of semi-SDs into hard capsules
Semi-SDs are often tacky and pose a problem of handling and storage. 
Stability problems are also seen in such formulations. A facile remedy 
for this problem is the direct filling of the liquid/semisolid melt of SD 
into hard capsules. Once filled by means of mechanical and automated 
filling devices such as dosators, the melt solidifies into the capsules. This 
circumvents the additional process of pulverization of the hardened 
mass, which speeds up production as well as reduces the chances of 
changes in the crystallinity of the SD on grinding. For example, in a 
research work, SDs of sparingly water-soluble drug amlodipine besylate 
were prepared and converted into a semisolid mass [35]. This mass 
was then filled in hard gelatin capsules. The results showed improved 
dissolution with a shortening of the lag time which meant a subsequent 
improvement in bioavailability.
CONCLUSION
The paradigm shift occurring in the pharmaceutical industry worldwide 
is the refocusing of efforts and financial resources into the development 
of formerly neglected poorly water-soluble drugs for oral drug delivery. 
SD has been one of the key technologies driving this shift. As newer 
hydrophobic molecules are discovered, instead of being discarded in 
the pipeline they are being given a new lease of life through innovative 
technologies as SDs. The synthesis of better excipients, polymers, 
and surfactants will offer many new avenues for the progress and 
development of better and novel SDs. With newer strategies employed, 
and with a deeper understanding of the molecular and thermodynamic 
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